BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Relay Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Relay Therapeutics\, Inc.'s drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07359820-10824@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Lyrfigtu (lirafugratinib): Phase 2 readout est. (NCT07359820)
DESCRIPTION:Lyrfigtu (lirafugratinib)\, phase 2.\nStudy: A Study of Lirafug
 ratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement\nEstima
 ted primary completion: September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lirafugratinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07359820
URL:https://assetmemo.bio/drug/lirafugratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982521-9083@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Zovegalisib: Phase 3 readout est. (NCT06982521)
DESCRIPTION:Zovegalisib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant
  as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- B
 reast Cancer\nEstimated primary completion: 30 April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zovegalisib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06982521
URL:https://assetmemo.bio/drug/zovegalisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789913-9083@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Zovegalisib: Phase 2 readout est. (NCT06789913)
DESCRIPTION:Zovegalisib\, phase 2.\nStudy: A Phase 2 Study of Mutant-select
 ive PI3Kα Inhibitor\, RLY-2608\, in Adults and Children With PIK3CA Relat
 ed Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The Re
 Inspire Study)\nEstimated primary completion: July 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/zovegalisib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06789913
URL:https://assetmemo.bio/drug/zovegalisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
